Clinical Trials Logo

Clinical Trial Summary

Primary goal of this study is the analysis of HLA (Human leucocyte antigen) formation in severly burned patients. Potential HLA triggers in the treatment of severely burned patients are blood products, assist devices or temporary allogeneic skin. Besides that, inflammatory markers, such as WBC (white blood cell count), CRP (C-reactive protein), PCT (Procalcitonin) and two novel biomarkers (PSP (pancreatic stone protein), ST2) are to be investigated in severely burned patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02537821
Study type Observational
Source University of Zurich
Contact Jan Plock, M.D.
Phone 0041 (0)44 2551111
Email jan.plock@usz.ch
Status Recruiting
Phase N/A
Start date June 2015